21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis

28.09.2005 - 01.10.2005
Please select a day:
28.09.2005
29.09.2005
30.09.2005
01.10.2005
Search

Personal programme
Please enter your email address here in order to bring up your personal programme




Home - 29.09.2005 - Therapy - immunomodulation - Part I


Therapy - immunomodulation - Part I

Thursday, September 29, 2005, 15:30 - 17:00

The efficacy of copaxone therapy in patients with secondary progressive multiple sclerosis

I. Zavalishin, B. Bejn, I. Sholomov, V. Alifirova, I. Poverennova, V. Baljazin, V. Okladnikov, D. Klushin, A. Peresedova, N. Stoida, M. Zaharova, L. Adarcheva, A. Nijazbekova, L. Askarova, V. Olejnikov, O. Rebrova, O. Durseneva, O. Kuranova, J. Orlova, K. Tel'nova, Z. Goncharova, L. Volkova, E. Turova, I. Okuneva, J. Nechaeva, L. Reikhert, S. Bychenko, O. Markina (Moscow, Kirov, Saratov, Tomsk, Samara, Rostov, Irkutsk, Tyumen, Ekaterinburg, RUS)

Background: The results of Copaxone therapy in more than four hundred patients with relapsing remitting multiple sclerosis (RRMS) in ten centers in Russia suggested that among these patients, 32 were with secondary progressive multiple sclerosis (SPMS) with relapses, that had been included in the study for various reasons. As the efficacy of Copaxone in patients with SPMS has until now not been assessed, we present in the current abstract the results of the two-year follow up of these SPMS patients with Copaxone.
Patients and Methods: Of the 32 patients with SPMS who were exposed to Copaxone 20mg daily sc therapy over 2 years, 21 were women and 11 were men. The mean age of the patients was 36.49.3 years. The duration of the disease, the number of relapses for the 2 years prior to the treatment with Copaxone and the EDSS score averaged 9.46.0 years, 2.81.4, and 4.80.9, respectively.
Results: This group of patients had a significant reduction of 54% in the number of relapses (1.3; p < 0.005). The number of patients experiencing relapses decreased from 94% to 68% (p < 0.001. It is noteworthy that a decrease in the number of relapses was evident as early as the first three to six months of Copaxone treatment and remained stable during the whole period of treatment. Furthermore, there was an increase in the number of patients with milder degrees of the condition resulting in a less severe relapses (from 10% to 25%, p < 0.05); this was accompanied by an increase in the number of patients in whom relapses resolved spontaneously (from 1% to 10%). No worsening in disability, as measured by EDSS, was noticed. The rate of only local adverse events fell from 12% to 5% of patients (p < 0.01) within the first few months of the therapy with no cases of their exacerbation during the whole period of the study.
Conclusion: The two-year follow up of a group of SPMS patients treated with Copaxone daily resulted in a decrease in the relapse rate and an increase in the number of patients free of relapses, as well as no further accumulation of disability for the whole duration of the study.